feasibility of the ipss-m in cmml
Published 11 months ago • 104 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
1:39
ipss-r vs ipss-m for mds
-
3:22
performance of the aipss-mds ml model in predicting os & leukemic transformation in cmml
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
1:18
the importance risk stratification to enable risk-adapted therapy in mds & cmml
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
2:03
the need to identify new treatment strategies in cmml & the potential of targeting inflammation
-
8:02
clinical presentation and symptoms of mds
-
1:29:13
myelodysplastic syndrome
-
6:04
a hematopathologist’s guide to identifying and subclassifying cmml
-
1:10
cmml: unmet needs and future outlooks
-
2:01
updates in mds diagnosis and prognosis with the ipss-m: personalized medicine in 2023
-
1:04
the future of mds management
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
2:45
the addition of venetoclax to hmas for the treatment of cmml: a retrospective psm analysis
-
2:41
an overview of the latest advances in hematology
-
1:26
current and emerging prognostic factors for mds/mpn
-
1:56
the feasibility of chemotherapy-free regimens without allogeneic transplantation in mrd- ph all
-
1:30
the prognostic value of patient-reported outcomes in mds
-
2:00
an update on the genomic landscape of mm
-
2:52
novel prognostic score for cmml patients undergoing sct
-
1:02
the impact of sequencing in aml